DE60325617D1 - Verfahren zur diagnose von bauchspeicheldrüsenkrebs - Google Patents

Verfahren zur diagnose von bauchspeicheldrüsenkrebs

Info

Publication number
DE60325617D1
DE60325617D1 DE60325617T DE60325617T DE60325617D1 DE 60325617 D1 DE60325617 D1 DE 60325617D1 DE 60325617 T DE60325617 T DE 60325617T DE 60325617 T DE60325617 T DE 60325617T DE 60325617 D1 DE60325617 D1 DE 60325617D1
Authority
DE
Germany
Prior art keywords
pancreatic cancer
pnc
methods
diagnosis
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60325617T
Other languages
English (en)
Inventor
Yusuke Nakamura
Toyomasa Katagiri
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oncotherapy Science Inc
Original Assignee
Oncotherapy Science Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc
Application granted granted Critical
Publication of DE60325617D1 publication Critical patent/DE60325617D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Hospice & Palliative Care (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Food Science & Technology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60325617T 2002-09-30 2003-09-17 Verfahren zur diagnose von bauchspeicheldrüsenkrebs Expired - Fee Related DE60325617D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41487202P 2002-09-30 2002-09-30
US45088903P 2003-02-28 2003-02-28
PCT/JP2003/011817 WO2004031412A2 (en) 2002-09-30 2003-09-17 Method for diagnosing pancreatic cancer

Publications (1)

Publication Number Publication Date
DE60325617D1 true DE60325617D1 (de) 2009-02-12

Family

ID=32073343

Family Applications (2)

Application Number Title Priority Date Filing Date
DE60325628T Expired - Lifetime DE60325628D1 (de) 2002-09-30 2003-09-12 Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen
DE60325617T Expired - Fee Related DE60325617D1 (de) 2002-09-30 2003-09-17 Verfahren zur diagnose von bauchspeicheldrüsenkrebs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE60325628T Expired - Lifetime DE60325628D1 (de) 2002-09-30 2003-09-12 Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen

Country Status (10)

Country Link
US (3) US7601826B2 (de)
EP (3) EP1556518B1 (de)
JP (2) JP4679149B2 (de)
CN (1) CN1703524B (de)
AT (2) ATE419391T1 (de)
AU (2) AU2003260966A1 (de)
CA (2) CA2500472A1 (de)
DE (2) DE60325628D1 (de)
ES (1) ES2320443T3 (de)
WO (2) WO2004031411A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US7790867B2 (en) 2002-12-05 2010-09-07 Rosetta Genomics Inc. Vaccinia virus-related nucleic acids and microRNA
US7888497B2 (en) 2003-08-13 2011-02-15 Rosetta Genomics Ltd. Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof
WO2005083086A2 (en) * 2004-02-27 2005-09-09 Oncotherapy Science, Inc. Epha4 as therapeutic target of prc and pdaca
US7939251B2 (en) * 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
IL179285A (en) 2004-05-14 2011-04-28 Rosetta Genomics Ltd Micrornas and uses thereof
US7687616B1 (en) 2004-05-14 2010-03-30 Rosetta Genomics Ltd Small molecules modulating activity of micro RNA oligonucleotides and micro RNA targets and uses thereof
US8843320B2 (en) 2004-05-21 2014-09-23 Board Of Trustees Of The University Of Arkansas Use of gene expression profiling to predict survival in cancer patient
US7795419B2 (en) 2004-05-26 2010-09-14 Rosetta Genomics Ltd. Viral and viral associated miRNAs and uses thereof
WO2006038904A2 (en) * 2004-08-06 2006-04-13 Applera Corporation Method and compositions for treating diseases targeting e-cadherin
DE102004042822A1 (de) * 2004-08-31 2006-03-16 Technische Universität Dresden Verbindungen und Methoden zur Behandlung, Diagnose und Prognose bei Pankreaserkrankungen
DE102004049897B4 (de) * 2004-10-13 2007-11-22 Sirs-Lab Gmbh Verfahren zur Unterscheidung zwischen nichtinfektiösen und infektiösen Ursachen eines Multiorganversagens
JP2009502735A (ja) * 2005-07-28 2009-01-29 オンコセラピー・サイエンス株式会社 Ｖｉｖｉｔポリペプチド、これを含む治療物質、および抗癌剤をスクリーニングする方法
DK1934615T3 (da) * 2005-09-19 2014-07-14 Janssen Diagnostics Llc Fremgangsmåder og materialer til identificering af oprindelsen af et karcinom med ukendt primær oprindelse
CN101415440A (zh) 2006-02-10 2009-04-22 肿瘤疗法科学股份有限公司 治疗肺癌的方法
CN101432022A (zh) 2006-02-28 2009-05-13 肿瘤疗法科学股份有限公司 利用抗-EphA4抗体效应物作用损伤细胞的方法
RU2008139098A (ru) * 2006-03-02 2010-04-10 Онкотерапи Сайенс, Инк. (Jp) Способы диагностики рака поджелудочной железы с применением белка reg4
CN1904072B (zh) * 2006-07-28 2012-07-18 浙江大学 一组筛选胰腺导管腺癌的基因组合及应用
EP2059593A2 (de) * 2006-08-18 2009-05-20 Oncotherapy Science, Inc. Behandlung oder vorbeugung von krebserkrankungen mit überexpression von reg4 oder kiaa0101
US7811778B2 (en) * 2006-09-06 2010-10-12 Vanderbilt University Methods of screening for gastrointestinal cancer
DK2140269T3 (da) 2007-03-27 2013-12-16 Immunovia Ab Proteinsignatur/markører til at detektere adenocarcinom
JP5294271B2 (ja) * 2007-08-20 2013-09-18 オンコセラピー・サイエンス株式会社 Ｃｄｈ３ペプチド及びこれを含む薬剤
WO2009025196A1 (ja) 2007-08-20 2009-02-26 Oncotherapy Science, Inc. Foxm1ペプチドおよびこれを含む薬剤
KR20110025215A (ko) 2008-06-30 2011-03-09 온코세라피 사이언스 가부시키가이샤 방사성 동위원소 표지로 표지된 항―ｃｄｈ３ 항체 및 이의 용도
TW201008574A (en) 2008-08-19 2010-03-01 Oncotherapy Science Inc INHBB epitope peptides and vaccines containing the same
CN102203250A (zh) * 2008-08-27 2011-09-28 肿瘤疗法科学股份有限公司 用于癌症治疗和诊断的靶基因syngr4
US10359425B2 (en) 2008-09-09 2019-07-23 Somalogic, Inc. Lung cancer biomarkers and uses thereof
US20100135991A1 (en) * 2008-11-17 2010-06-03 Chiu-Chen Huang Antibodies recognizing oxygen-regulated protein 150 expressed on cancer cells and methods of using same
TWI469791B (zh) 2009-02-18 2015-01-21 Oncotherapy Science Inc Ｆｏｘｍ１胜肽以及含此胜肽之疫苗
DE102010043541B4 (de) * 2009-12-16 2012-01-26 Technische Universität Dresden Verfahren und Mittel zur Vorhersage der Überlebensdauer beim Pankreaskarzinom durch Analyse von Biomarkern
DK2519542T3 (en) 2009-12-28 2019-01-14 Onco Therapy Science Inc ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF.
US20130137748A1 (en) * 2010-02-03 2013-05-30 Oncotherapy Science, Inc. Whsc1 and whsc1l1 for target genes of cancer therapy and diagnosis
CA2800023A1 (en) * 2010-06-01 2011-12-08 Metanomics Health Gmbh Means and methods for diagnosing pancreatic cancer in a subject
SG10201508656VA (en) 2010-07-09 2015-11-27 Somalogic Inc Lung cancer biomarkers and uses thereof
AU2011289284B2 (en) * 2010-08-13 2015-04-09 Somalogic Operating Co., Inc. Pancreatic cancer biomarkers and uses thereof
WO2012048113A2 (en) 2010-10-07 2012-04-12 The General Hospital Corporation Biomarkers of cancer
KR101297336B1 (ko) 2011-03-30 2013-08-14 인하대학교 산학협력단 점액성 낭성종양 진단 장치
KR101223598B1 (ko) 2011-04-06 2013-01-22 인하대학교 산학협력단 췌장 상피내 종양 진단 시스템
EP2771685B1 (de) * 2011-10-24 2018-06-13 The General Hospital Corporation Krebsbiomarker
WO2014189843A1 (en) 2013-05-20 2014-11-27 Board Of Trustees Of The University Of Arkansas Gep5 model for multiple myeloma
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
MX2016011612A (es) * 2014-03-11 2016-12-12 The Council Of The Queensland Inst Of Medical Res Determinacion de agresividad, pronostico y responsividad del cancer al tratamiento.
EP3198030B1 (de) 2014-09-26 2020-11-04 HI-STEM gGmbH Im Deutschen Krebsforschungszentrum DKFZ Neuartige verfahren zur subtypisierung und behandlung von krebs
GB201501930D0 (en) 2015-02-05 2015-03-25 Univ London Queen Mary Biomarkers for pancreatic cancer
JP2018136122A (ja) * 2015-05-29 2018-08-30 国立研究開発法人国立がん研究センター 膵がんを診断するための血漿バイオマーカーパネル
CN105017403B (zh) * 2015-07-09 2018-07-03 陈勇 胰腺癌相关多肽dap44单克隆抗体的制备及其应用
SG11201802881YA (en) 2015-10-08 2018-05-30 Oncotherapy Science Inc Foxm1-derived peptide, and vaccine including same
EP3683311A4 (de) * 2017-09-11 2021-06-02 National University Corporation Hokkaido University Arzneimittel zur krebsbehandlung
EP3508855A1 (de) * 2018-01-05 2019-07-10 Allianz Pharmascience Ltd Verfahren zur auswahl von patienten und kit
KR102328654B1 (ko) * 2019-04-17 2021-11-19 한국원자력의학원 암의 예방 또는 치료용 약학 조성물
KR102289278B1 (ko) * 2019-07-09 2021-08-13 주식회사 베르티스 췌장암 진단용 바이오마커 패널 및 그 용도
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
CN115074365B (zh) * 2022-06-28 2023-02-28 中国医学科学院北京协和医院 靶向GATM基因的sgRNA及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744101A (en) 1989-06-07 1998-04-28 Affymax Technologies N.V. Photolabile nucleoside protecting groups
AU7499198A (en) 1997-05-21 1998-12-11 Johns Hopkins University, The Gene expression profiles in normal and cancer cells
EP1038030A2 (de) 1997-12-15 2000-09-27 Abbott Laboratories Reagenzien und methoden geeignet zur detektion von pankrease-erkrankungen
US6262249B1 (en) 1998-06-23 2001-07-17 Chiron Corporation Pancreatic cancer genes
WO2001064835A2 (en) * 2000-02-28 2001-09-07 Hyseq, Inc. Novel nucleic acids and polypeptides
US20020119158A1 (en) * 1998-12-17 2002-08-29 Corixa Corporation Compositions and methods for the therapy and diagnosis of ovarian cancer
US6429302B1 (en) * 1999-02-02 2002-08-06 Chiron Corporation Polynucleotides related to pancreatic disease
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
WO2001009318A1 (fr) 1999-07-29 2001-02-08 Helix Research Institute Genes associes au cancer du foie
CA2492070A1 (en) 1999-12-01 2001-06-07 Kevin P. Baker Lung tumor marker pro4329 polypeptides and nucleic acids encoding the same
WO2001055321A2 (en) * 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
WO2001094629A2 (en) 2000-06-05 2001-12-13 Avalon Pharmaceuticals Cancer gene determination and therapeutic screening using signature gene sets
US6974667B2 (en) 2000-06-14 2005-12-13 Gene Logic, Inc. Gene expression profiles in liver cancer
AU2002255478A1 (en) * 2001-01-10 2002-09-12 Pe Corporation (Ny) Kits, such as nucleic acid arrays, comprising a majority of human exons or transcripts, for detecting expression and other uses thereof
EP1504099A4 (de) 2001-12-10 2006-05-10 Nuvelo Inc Neue nukleinsäuren und polypeptide
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US20050260639A1 (en) 2002-09-30 2005-11-24 Oncotherapy Science, Inc. Method for diagnosing pancreatic cancer
US20060194199A1 (en) 2002-09-30 2006-08-31 Oncotherapy Science, Inc. Method for diagnosing testicular seminomas
RU2008139098A (ru) * 2006-03-02 2010-04-10 Онкотерапи Сайенс, Инк. (Jp) Способы диагностики рака поджелудочной железы с применением белка reg4

Also Published As

Publication number Publication date
JP2006500947A (ja) 2006-01-12
US7601826B2 (en) 2009-10-13
CA2500472A1 (en) 2004-04-15
EP1556518B1 (de) 2008-12-31
AU2003260966A1 (en) 2004-04-23
JP4679149B2 (ja) 2011-04-27
AU2003263603A1 (en) 2004-04-23
US20120028262A1 (en) 2012-02-02
AU2003260966A8 (en) 2004-04-23
US20060270619A1 (en) 2006-11-30
EP1549771B1 (de) 2008-12-31
EP2009117A2 (de) 2008-12-31
WO2004031411A2 (en) 2004-04-15
CA2500482A1 (en) 2004-04-15
ES2320443T3 (es) 2009-05-22
JP2006500948A (ja) 2006-01-12
ATE419391T1 (de) 2009-01-15
ATE419390T1 (de) 2009-01-15
US7943730B2 (en) 2011-05-17
CN1703524B (zh) 2010-04-07
US20100093629A1 (en) 2010-04-15
CN1703524A (zh) 2005-11-30
EP1549771A2 (de) 2005-07-06
WO2004031411A3 (en) 2004-09-30
WO2004031412A3 (en) 2004-07-15
EP2009117A3 (de) 2009-03-18
AU2003263603A8 (en) 2004-04-23
EP1556518A2 (de) 2005-07-27
WO2004031412A2 (en) 2004-04-15
DE60325628D1 (de) 2009-02-12

Similar Documents

Publication Publication Date Title
ATE419390T1 (de) Verfahren zur diagnose von bauchspeicheldrüsenkrebs
ATE508202T1 (de) Verfahren zur diagnose von brustkrebs
DE60233485D1 (de) Verfahren zur diagnose, behandlung und prävention von knochenverlust
WO2004031409A3 (en) Method for diagnosing chronic myeloid leukemia
WO2007013575A3 (en) Method for diagnosing and treating renal cell carcinoma
WO2004031410A3 (en) Method for diagnosing testicular seminomas
ATE546734T1 (de) Risikomarker für eine herzkreislaufkrankheit
ATE423217T1 (de) Assays zur überwachung von krebspatienten auf grundlage der spiegel von analytenkomponenten des plasminogen-aktivator-systems in proben von körperflüssigkeiten
CY1117839T1 (el) Γονιδιο τομ34 σχετιζομενο με καρκινο του παχεος εντερου
ATE514948T1 (de) In vitro verfahren zur diagnose von neurodegenerativen erkrankungen
WO2004031414A3 (en) Method for diagnosing prostate cancer
WO2007013360A3 (en) Pancreatic cancer related gene cst6 and gabrp
ATE354097T1 (de) Verfahren zur diagnose von leberfibrose.
TW200643176A (en) ZNFN3A1/breast cancer related gene ZNFN3A1
WO2004007770A3 (en) Method for diagnosis of intestinal-type gastric tumors
ATE422671T1 (de) Verfahren zur diagnose von morbus alzheimer
WO2004038045A3 (en) Method for diagnosing diffuse-type gastric cancer
DE602005023329D1 (de) VERFAHREN ZUR DIAGNOSE NICHT-KLEINZELLIGER LUNGENKARZINOME ÜBER DIE tRNA-DIHYDROURIDIN-SYNTHASEAKTIVITÄT VON URLC8
WO2005083118A3 (en) Pin-prc transition genes
DE60038614D1 (de) Verfahren zur diagnose von synovialen oder osteoartikulären erkrankungen
DE602004027534D1 (de) Diagnostische verfahren für therapeutische verbindungen sowie verfahren zur überwachung der azathioprin-therapie
WO2007013359A3 (en) Cancer related gene rasgef1a
DE602005023973D1 (de) Verfahren zur diagnose von chronischem stress und verwandten erkrankungen
DE60225845D1 (de) Zusammensetzungen und verfahren zur diagnose und behandlung von diabetes, insulinresistenz und dyslipidämie
DE60329224D1 (de) Verfahren zur Bestimmung von zirkulierender DNS in Plasma und zum Nachweis von Krebs

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee